Ralimetinib
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor. A phase II trial for treatment of ovarian cancer has completed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1332214974 under CC BY-SA 4.0; modifications have been made.